Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05361122

Prevention of Developmental Delay and Xylitol (PDDaX) Study

The goals of this study are to: evaluate and validate the low-cost, transportable, easily-administered Malawi Developmental Assessment Tool (MDAT) for neurodevelopmental assessment of children aged 4-8 years old in Malawi, as compared to the gold-standard yet more cumbersome and costly Kaufman Assessment Battery for Children-II (KABC-II) among (1) n=500 formerly preterm children and (2) n=500 formerly term children.

Additionally, we will evaluate the effects of gestational xylitol exposure compared to a lack of gestational xylitol exposure on neurodevelopmental outcomes of children aged 4-8 years old in Malawi through the following four neurodevelopmental tests: (3) KABC-II (cognitive outcomes), (4) EF Touch (executive functions), (5) Strengths and Difficulties Questionnaire (social-emotional outcomes), and (6) MDAT (motor and cognitive outcomes).

The researchers will leverage subjects who completed the parent Prevention of Prematurity and Xylitol Trial, which enrolled 10069 pregnant individuals in Malawi and demonstrated a significant 24% reduction in incidence of preterm birth and low birthweight offspring in gravidae who chewed xylitol-containing chewing gum compared to those who did not. By ensuring that these offspring did not have higher rates of neurodevelopmental impairment, the study will promote promising multi-center international and domestic trial evaluating the impact of xylitol-containing chewing gum use and optimal dosage during pregnancy.

Recruiting

Interested in participating?

Request Info

Key information

Age range

4 year–8 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Baylor College of Medicine Children's Foundation-Malawi

Lilongwe, Malawi

Location status: Recruiting

Location contact

Phoebe Nyasulu

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Child born during the PPaX trial
  • Enrollment age between 4-8 years old
  • Parental or legal guardian consent obtained
  • Willing to undergo 3 neurodevelopmental tests
  • Willing to travel to BCMF for neurodevelopmental assessment
  • Assent by the pediatric subject for participation in the study

Exclusion criteria

  • Parent or legal guardian cognitively unable to provide consent
  • Child unwilling to provide assent to participate in the study

Treatment and study plan

Maternal Use of Xylitol Chewing Gum During Pregnancy

Dietary Supplement

There are no current interventions within this follow-up study. However, the mothers enrolled in the parent PPaX trial received xylitol-containing chewing gum (1 gram per stick of gum and instructed to chew 1-2 sticks of gum twice daily for a total dose of 2-4 grams/day of xylitol throughout pregnancy starting pre-conception or at <20 weeks gestation).

No Maternal Xylitol Chewing Gum Use During Pregnancy

Dietary Supplement

There are no current interventions within this follow-up study. Children born to mothers who received access to a dentist and prenatal education (oral health, prevention of preterm birth) are in the active comparator group

Primary outcomes

  1. Validation of the MDAT in Former Preterm Children

    Time frame: 1 month (1-2 clinic visits)

    compared to the KABC-II

  2. Validation of the MDAT in Former Term Children

    Time frame: 1 month (1-2 clinic visits)

    compared to the KABC-II

  3. KABC-II mental processing index

    Time frame: 1 month (1-2 clinic visits)

    In n=500 former term and n=500 former preterm children aged 4-8 years old with half of each being gestationally xylitol exposed vs not exposed

  4. EF Touch composite score

    Time frame: 1 month (1-2 clinic visits)

    In n=500 former term and n=500 former preterm children aged 4-8 years old with half of each being gestationally xylitol exposed vs not exposed

  5. SDQ composite

    Time frame: 1 month (1-2 clinic visits)

    In n=500 former term and n=500 former preterm children aged 4-8 years old with half of each being gestationally xylitol exposed vs not exposed

  6. MDAT composite neurodevelopmental outcome

    Time frame: 1 month (1-2 clinic visits)

    In n=500 former term and n=500 former preterm children aged 4-8 years old with half of each being gestationally xylitol exposed vs not exposed

Secondary outcomes

  1. Incidence of cognitive delay per specific KABC-II subdomain

    Time frame: 1 month (1-2 clinic visits)

    sequential processing (working memory), simultaneous processing (visual processing), planning ability (fluid reasoning), and learning ability (long-term memory and retrieval)

  2. Incidence of executive function delay per specific EF Touch subdomains

    Time frame: 1 month (1-2 clinic visits)

    processing speed ("Bubbles"), visual spatial working memory ability ("Farmer"), working memory ("Pick the Picture" and "Houses"), inhibitory motor control ("Pig", "Silly Sounds Game", and "Arrows"), and Flexible thinking ("Something's the Same")

  3. Incidence of social-emotional delay per specific SDQ subdomains

    Time frame: 1 month (1-2 clinic visits)

    Emotional symptoms, conduct problems, hyperactivity/inattention, peer relationship problems, and prosocial behavior

  4. Incidence of neurodevelopmental delay as per MDAT subdomains

    Time frame: 1 month (1-2 clinic visits)

    Gross motor, fine motor, social, and language

Study contacts

Contact information is provided by the study sponsor or research team.

Greg Valentine, MD

CONTACT

[email protected]

(206) 543-3200

Sponsors and collaborators

Lead sponsor

University of Washington

Other

Registry information

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
May 4, 2022
Registry last updated
Mar 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.